Benjamin F. Edwards & Company, Inc. Astria Therapeutics, Inc. Transaction History
Benjamin F. Edwards & Company, Inc.
- $5.69 Billion
- Q2 2024
Shares
1 transactions
Others Institutions Holding ATXS
# of Institutions
104Shares Held
49.4MCall Options Held
27.6KPut Options Held
29.7K-
Perceptive Advisors LLC New York, NY6.49MShares$77.6 Million1.71% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.04MShares$60.4 Million0.69% of portfolio
-
Vr Adviser, LLC New York, NY3.61MShares$43.2 Million3.6% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.55MShares$42.5 Million6.42% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$42.1 Million0.0% of portfolio
About Astria Therapeutics, Inc.
- Ticker ATXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,178,000
- Market Cap $182M
- Description
- Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...